WO2023057946 - SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES
National phase entry:
Publication Number
WO/2023/057946
Publication Date
13.04.2023
International Application No.
PCT/IB2022/059548
International Filing Date
06.10.2022
Title **
[English]
SERUM HALF-LIFE EXTENDED PD-L1 BINDING POLYPEPTIDES
[French]
POLYPEPTIDES SÉRIQUES DE LIAISON PD-L1 PROLONGÉS À DEMI-VIE
Applicants **
AVACTA LIFE SCIENCES LIMITED
Inventors
BASRAN, Amrik
JENKINS, Emma
ADAM, Estelle
STANLEY, Emma
WRITER, Michele
Priority Data
63/253,446
07.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6324 | |
| EPO | Filing, Examination, Granting | 52667 | |
| Japan | Filing, Examination, Granting | 3712 | |
| South Korea | Filing, Examination, Granting | 5473 | |
| USA | Filing, Examination, Granting | 18240 |
Total:
86,416
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides engineered PD-L1-binding Stefin A polypeptide variants, polynucleotides encoding the engineered PD-L1-binding Stefin A polypeptide variants, cells expressing the polypeptide variants, pharmaceutical preparations of the polypeptide variants, and uses of the polypeptide variants in the treatment of various human conditions, including cancer.[French]
La présente divulgation concerne des variants polypeptidiques modifiés de la stéfine A se liant à PD-L1, des polynucléotides codant pour ces variants polypeptidiques modifiés de la stéfine A se liant à PD-L1, des cellules exprimant lesdits variants polypeptidiques, des préparations pharmaceutiques desdits variants polypeptidiques et des utilisations desdits variants polypeptidiques dans le traitement de diverses affections humaines, notamment le cancer.